Each tablet contain Azithromycin dihydrate USP equivalent to Azithromycin, 500mg
In adults, children over 14 years and those body weights greater than 45kg, Azithromycin should be given as 500 mg once daily orally for 3 days or as an alternative, given over 5 days with 500 mg on day 1, then 250 mg on days 2-5. For sexually transmitted diseases caused by Chlamydia trachomatis the dose is 1 g given as a single dose.
1. Lower respiratory tract infections: Acute bacterial bronchitis due to Streptococcus pneumoniae, Haemophilus influenza or Moraxella carterrhalis; Community-acquired pneumonia due to Streptococcus pneumoniae or Haemophilus influenza in patients suitable for outpatient oral treatment; Community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. In clinical studies efficacy has been demonstrated again Chlamydia, Haemophilus influenza, Legionella pneumophilia, Moraxella catarrhalis, Mycoplasma pneumonia, Staphylococcus aureus and Streptococcus pneumoniae. 2. Upper respiratory infections: Acute sinusitis due to Streptococcus pneumonia or Haemophilus influenza; Acute Streptoccocal pharyngitis due to Streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. 3. Acute otitis media. 4. Uncomplicated skin and skin structure infections: Uncomplicated infections due to Staphylococcus aureus, Streptococcus pyogenes or Streptococcus agalactiae; Abscesses usually require surgical drainage 5. Sexually transmitted diseases: Uncomplicated urethritis and cervcitis due to Chlamydia trachomatis or non - multiresistant Neisseria gonorrhea; Pelvic inflammatory disease caused by susceptible organisms, (Chlamydia trachomatis, Neisseria gonorrhea, Mycoplasma hominis) in patients who require initial intravenous therapy. 6. Chlamydia trachomatis conjunctivitis and trachoma. 7. Prevention due to Mycobacterium avium-intracellulare Complex (MAC) Disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults with HIV infection and Cd$ cell count less than or equal to 75 cells/µL.
1. Hypersensitivity to Azithromycin or any macrodile antibiotics 2. Coadministration with ergot derivatives. Relative contraindications: 1. Hepatic disease 2. Pregnancy and lactation
In the treatment of pneumonia, Azithromycin has been shown to be safe and effective only in the treatment of community-acquired pneumonia of mild severity due to Streptococcus pneumoniae or Haemophilus influenzae in patients appropriate for outpatient oral therapy. Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for outpatient oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, nosocomial infection, known or suspected bacteremia, requiring hospital admission, elderly or debilitated patients or with significant underlying health problems.
ASIA PACIFIC - PHILIPPINES
2204-C West Tektite Tower, Philippine Stock Exchange Center Exchange Rd.,
Ortigas Center, Pasig City,
Verheilen Pharmaceuticals Inc. © 2015 All rights reserved.